Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events

Show other versions (1)

Abstract Immune checkpoint inhibitors (ICIs) are able to reactivate the immune system, thereby enhancing the anti‐tumor effects. However, over‐activated T cells may induce immune‐related adverse events (irAEs). Hematological irAEs are rarely reported which mainly represent monolineage cytopenia or p...

Full description

Bibliographic Details
Main Authors: Junling Zhuang, Jianhua Du, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Wei Qiu, Xiaoyan Si, Li Zhang, Yue Li, Xiaowei Liu, Hanping Wang, Daobin Zhou
Format: Article
Language:English
Published: Wiley 2020-03-01
Series:Thoracic Cancer
Subjects:
Cytopenia
immune checkpoint inhibitors
immune‐related adverse events
Online Access:https://doi.org/10.1111/1759-7714.13281

Internet

https://doi.org/10.1111/1759-7714.13281

Similar Items